Global Market

Sanzyme is a well-established brand in the Indian biopharmaceuticals market and has now started expanding its reach across other parts of the world. Our experience in the field of infertility management of over half a century gives us an edge over any other manufacturer entering the world market.

Few areas of manufacturing infertility medicines require expertise, and we take pride in the fact that we are experts in every facet of manufacturing the finished product. Our expertise lies in urine collection, intermediate preparation, purification of API,  Fill and finish formulation, and analytical testing per regulatory standards.

The state-of-the-art research facilities, world-class manufacturing setup, and superior technical know-how make Sazyme a robust and reliable player in the market. This infrastructure also gives every reason for Sanzyme to spread its wings into the world market, addressing infertility issues on a global scale.

Why are we Going Global?

The world market for fertility drugs was at $3.94 billion in 2021 and is expected to grow to $ 4.83 billion by the end of 2025. The CAGR is said to be at 5%, which is substantial. According to the USA National Survey of Family Growth (NSFG) in 2018, infertility has affected about 15.5% of all women who intend to become pregnant. The rising cases of infertility across the globe have led to an increased market potential for fertility drugs.

Sanzyme’s B2B Approach

Sanzyme has set foot in the global market by offering to contract-manufacture its world-class fertility drugs and gonadotropins to pharmaceutical marketing companies across 20 countries. Currently, Sanzyme is in the process of forging relationships with pharma giants to create a global market for Sanzyme’s products. Sazyme intends to establish a solid network to facilitate the global reach of its infertility and gonadotropin drugs through this strategy of out-contacting its production. Sanzyme also plans to collaborate with fertility treatment centers worldwide, supplying them world class human-derived gonadotropins.

Sanzyme’s B2C Approach

There is a vast potential for fertility drugs worldwide. With its legacy of being a leader in manufacturing and supplying the best-in-class products in India, Sanzyme has now chosen to partner with the world’s leading pharma companies as a contract manufacturer and enable Sanzyme’s powerful formulations to reach end consumers under partner companies’ brand names. Sanzyme aims to reach every prospective parent across the globe and reach the aisle of every drug store.